AstraZeneca PLC - American Depositary Shares (NQ:AZN)

92.77 UNCHANGED

Last Price Updated: 4:00 PM EST, Jan 30, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about AstraZeneca PLC - American Depositary Shares

< Previous 1 2

...

9 10 11 12 13 14 15 16 17

...

75 76 Next >

Lowey Dannenberg Notifies AstraZeneca PLC (“AstraZeneca” or the “Company”) (NASDAQ: AZN) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $200,000 in Losses to Contact the Firm

January 31, 2025

From Lowey Dannenberg, P.C.

Via GlobeNewswire

ROSEN, THE FIRST FILING FIRM, Encourages AstraZeneca PLC Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – AZN

January 30, 2025

From The Rosen Law Firm PA

Via GlobeNewswire

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against AstraZeneca, IIPR, Block, and Crocs and Encourages Investors to Contact the Firm

January 29, 2025

From Bragar Eagel & Squire

Via GlobeNewswire

RFK Jr. And Big Pharma: Health Secretary Hopeful Answers Pointed Questions On Drugs, Insurance, Trump Exec Orders ↗

January 29, 2025

Kennedy seeks to be Secretary of Health and Human Services — a position that would put him in charge of the health of the American people.

Via Benzinga

Topics Government

DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of AstraZeneca

January 29, 2025

From Faruqi & Faruqi LLP

Via GlobeNewswire

FDA Approves AstraZeneca, Daiichi Sankyo's Enhertu For Certain Type Of Breast Cancer Patients ↗

January 28, 2025

FDA approves Enhertu for metastatic breast cancer with HER2-low or HER2-ultralow expression after showing significant efficacy in the DESTINY-Breast06 trial.

Via Benzinga

ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as first HER2-directed therapy for patients with HER2-low or HER2-ultralow metastatic breast cancer following disease progression after one or more endocrine therapies

January 27, 2025

From AstraZeneca

Via Business Wire

ROSEN, THE FIRST FILING FIRM, Encourages AstraZeneca PLC Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – AZN

January 27, 2025

From The Rosen Law Firm PA

Via GlobeNewswire

ROSEN, THE FIRST FILING FIRM, Encourages AstraZeneca PLC Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – AZN

January 24, 2025

From The Rosen Law Firm PA

Via GlobeNewswire

January 24, 2025

From Lowey Dannenberg, P.C.

Via GlobeNewswire

AstraZeneca To Pump $570 Million Into Canada, Driving Expansion, Job Growth ↗

January 24, 2025

AstraZeneca invests $570 million in Canada, expands facilities, and boosts R&D efforts, aiming to deliver 20 new medicines globally by 2030.

Via Benzinga

Robbins LLP Encourages AZN Shareholders with Large Losses to Seek Counsel in the AstraZeneca PLC Class Action

January 22, 2025

From Robbins LLP

Via GlobeNewswire

Cytokinetics Heart Drug's Future Sparks Optimism Despite M&A Hurdles and Royalty Deal Concerns: Analyst ↗

January 22, 2025

Cytokinetics receives a Buy rating from Stifel, with a promising outlook for aficamten in the $3 billion U.S. oHCM market, despite investor concerns over M&A and deals.

Via Benzinga

Analyst Praises AMD-Partner Absci's Practical Approach, Sees 118% Stock Upside ↗

January 22, 2025

Needham initiated a Buy rating for Absci (ABSI), noting its AI-powered drug discovery platforms, strategic partnerships, and $9 price target.

Via Benzinga

DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of AstraZeneca

January 22, 2025

From Faruqi & Faruqi LLP

Via GlobeNewswire

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages AstraZeneca PLC Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – AZN

January 21, 2025

From The Rosen Law Firm PA

Via GlobeNewswire

Demand for Advanced Pancreatic Cancer Treatments at All Time High as Promising Options Come into Focus

January 22, 2025

From FN Media Group LLC

Via GlobeNewswire

ASTRAZENECA ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against AstraZeneca PLC and Encourages Investors to Contact the Firm

January 21, 2025

From Bragar Eagel & Squire

Via GlobeNewswire

FDA Approves AstraZeneca's Datroway For Pretreated Breast Cancer Patients ↗

January 21, 2025

AstraZeneca's Datroway gains FDA approval for HR-positive, HER2-negative breast cancer after prior therapies, based on Phase 3 trial data.

Via Benzinga

Beyond Rigetti: Top 3 Quantum Computing Stock Picks

January 21, 2025

Quantum computing is in its early stages, but investors may benefit from the incremental progress being made by these three companies

Via MarketBeat

Topics Artificial Intelligence

3 Unstoppable Dividend-Growth Stocks Yielding More Than 3% That Income-Seeking Investors Want to Buy in 2025 and Hold Forever ↗

January 21, 2025

Via The Motley Fool

ROSEN, THE FIRST FILING FIRM, Encourages AstraZeneca PLC Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – AZN

January 18, 2025

From The Rosen Law Firm PA

Via GlobeNewswire

DATROWAY® (datopotamab deruxtecan-dlnk) approved in the US for patients with previously treated metastatic HR-positive, HER2-negative breast cancer

January 17, 2025

From AstraZeneca

Via Business Wire

AstraZeneca Aims to Restore Trust With New Leadership in China Amid Scandal and Sales Decline ↗

January 17, 2025

AstraZeneca restructures its China operations following leadership scandals and sales challenges, appointing new executives and focusing on innovative cancer drugs.

Via Benzinga

January 17, 2025

HHS adds 15 drugs to Medicare Part D price negotiations, targeting cost reductions under the Inflation Reduction Act. New prices aim to save billions by 2027.

Via Benzinga

Topics Economy

FDA Approves AstraZeneca's Calquence Combo Therapy For Untreated Mantle Cell Lymphoma ↗

January 17, 2025

AstraZeneca's Calquence gains FDA approval for untreated mantle cell lymphoma, supported by data showing improved survival and reduced disease progression.

Via Benzinga

January 17, 2025

From Lowey Dannenberg, P.C.

Via GlobeNewswire

Faruqi & Faruqi Reminds AstraZeneca Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 21, 2025 – AZN

January 17, 2025

From Faruqi & Faruqi LLP

Via GlobeNewswire

CALQUENCE® (acalabrutinib) plus chemoimmunotherapy approved in the US for patients with previously untreated mantle cell lymphoma

January 17, 2025

From AstraZeneca

Via Business Wire

3 High-Yielding Dividend Stocks That Are Trading at Dirt Cheap Prices ↗

January 15, 2025

Via The Motley Fool

< Previous 1 2

...

9 10 11 12 13 14 15 16 17

...

75 76 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.